- Multiparametric MRI (mpMRI) avoids biopsy in over 50% of patients with suspected prostate cancer; 94.1% of these individuals were free of cancer diagnosis 6 years later.
Why this matters
- This study underscores the importance of mpMRI in the diagnostic workup in clinical setting.
- Limited data are available on follow-up in patients with negative mpMRI scans.
- Study of 4259 patients (median age was 65 years) with clinical suspicion for prostate cancer who received first prostate mpMRI between 2012 and 2017.
- Funding: None disclosed.
- 53.6% of patients had negative mpMRI (Prostate Imaging Reporting And Data System [PI‐RADS] ≤2 lesions).
- In patients with negative mpMRI, cancer diagnosis‐free survival was 99.6% after 3 years and 94.1% at 6 years.
- In patients with PI-RADS 3, 4, and 5, immediate biopsy detected clinically significant cancer in 15.8%, 43.2%, and 74.5% of patients, respectively.
- In 320 patients with PI‐RADS ≤2, 10.6% of follow‐up mpMRI (median, 57 months) were classified as PI-RADS 4/5.
- In 108 patients with PI-RADS 3 who underwent mpMRI at median of 41 months, 11.1% of mpMRI were classified as PI-RADS 4/5.
- Age was a predictor for clinically significant cancer during follow‐up (P<.05>
- Retrospective design.